Saxenda one-month results: what the evidence says about early GLP-1 weight loss
Quick answer
The creator is using Saxenda (liraglutide 3.0 mg), a GLP-1 receptor agonist approved for chronic weight management, and reports a 3 kg loss in month one alongside resolution of early nausea at approximately 2.5 weeks. Their description of post-meal pain is consistent with liraglutide's documented effects on gastric emptying and altered satiety signaling. Clinical trial data from the SCALE program supports both the weight loss trajectory and the adverse event profile they describe.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @vero_avud actually say?
After one month on Saxenda (liraglutide), this creator reported losing about three kilograms (roughly 6.6 lbs) without changing their diet. They said nausea resolved after two and a half weeks, described significant pain after overeating, and attributed that pain to Saxenda slowing gastric emptying. They framed the slow start as a positive, giving the body time to adjust.
To be clear about the scope here: this is a personal experience video, not a medical claim video. The creator isn't telling you to take Saxenda or prescribing anything. They're documenting what happened to them. That matters when fact-checking, because the standard isn't "did they cite a study" but "is what they described consistent with how this drug actually works?"
Short answer: mostly yes, with one framing issue worth flagging.
Does the science back this up?
The weight loss figure and the nausea timeline are both plausible based on clinical trial data. Three kilograms in a month without dietary changes is within the expected range for early liraglutide treatment, especially at the dose-escalation phase. The gastric emptying explanation is real, though slightly oversimplified.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that patients on liraglutide 3.0 mg lost an average of 8.4 kg over 56 weeks compared to 2.8 kg on placebo. Month-one losses vary widely by individual, but 3 kg is reasonable. Nausea is the most commonly reported adverse event with liraglutide, affecting roughly 40 percent of users in early trials, and it typically diminishes as the body adjusts, which is consistent with the creator's two-and-a-half-week timeline. The mechanism behind the overeating pain is also real: liraglutide delays gastric emptying via GLP-1 receptor activation, meaning food stays in the stomach longer, and pushing past satiety signals can cause genuine discomfort (van Can et al., 2014, International Journal of Obesity).
What did they get wrong (or right)?
The creator got more right than wrong here. The nausea timeline, the satiety mechanism, and the weight loss figure are all consistent with clinical evidence. Give credit where it's due.
The one framing issue: they said Saxenda "keeps your food in your body for longer" as the explanation for the overeating pain. That's partially correct. Delayed gastric emptying is a real liraglutide effect, but the more significant driver of satiety and discomfort is central appetite suppression via GLP-1 receptors in the hypothalamus, combined with slowed gut motility. The stomach isn't just a holding tank that fills up, the brain is also receiving different signals about fullness. This distinction matters because it affects how people think about the drug's risks: it's not just about eating volume, it's about the entire gut-brain signaling axis being altered.
Also worth noting: "I haven't changed anything in my diet" is presented as a positive, and while it's honest, it's not ideal medical practice. GLP-1 medications are typically most effective when paired with dietary changes (Wadden et al., 2013, Obesity). Not wrong, just incomplete as standalone advice to viewers who might take it as a green light to eat freely on Saxenda.
What should you actually know?
If you're watching this video and considering Saxenda, here are the things this creator didn't cover but you probably should understand before starting.
- Saxenda requires a prescription and is indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It's not a casual supplement.
- The drug is dose-escalated over several weeks specifically to reduce nausea, starting at 0.6 mg daily and increasing to 3.0 mg. What dose the creator is on isn't mentioned, which affects how to interpret their results.
- Three kilograms in month one is encouraging, but long-term data shows that many patients regain weight after stopping liraglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism). This is a long-term treatment decision, not a short-term fix.
- The overeating pain the creator described is a real signal worth taking seriously. Pushing past fullness on GLP-1 medications has been associated with increased risk of gastroparesis in susceptible individuals, though this is more commonly flagged with higher-potency GLP-1 agents.
- Saxenda and compounded liraglutide are not the same product. If you're being offered compounded liraglutide at a lower price, that is a different product with different regulatory oversight.
The bottom line
This is one of the more grounded GLP-1 personal experience videos on TikTok. The creator isn't making wild claims, isn't selling anything, and is being reasonably honest about their experience. The science largely supports what they described. The gaps are about mechanism nuance and the missing context around diet, not misinformation. For 117,000 viewers who are curious about what month one actually feels like, this is a relatively responsible share.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda one-month results: what the evidence says about early GLP-1 weight loss, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda one-month results: what the evidence says about early GLP-1 weight loss is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is using Saxenda (liraglutide 3.
FormBlends verdict
The creator is using Saxenda (liraglutide 3.0 mg), a GLP-1 receptor agonist approved for chronic weight management, and reports a 3 kg loss in month one alongside resolution of early nausea at approximately 2.5 weeks. Their description of post-meal pain is consistent with liraglutide's documented effects on gastric emptying and altered satiety signaling. Clinical trial data from the SCALE program supports both the weight loss trajectory and the adverse event profile they describe.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is using Saxenda (liraglutide 3.0 mg), a GLP-1 receptor agonist approved for chronic weight management, and reports a 3 kg loss in month one alongside resolution of early nausea at approximately 2.5 weeks. Their description of post-meal pain is consistent with liraglutide's documented effects on gastric emptying and altered satiety signaling. Clinical trial data from the SCALE program supports both the weight loss trajectory and the adverse event profile they describe.
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found average liraglutide users lost 8.4 kg over 56 weeks, making a 3 kg first-month result plausible but individual variation is high.
- Nausea affects up to 40 percent of liraglutide users and typically resolves during the dose-escalation phase, consistent with the creator's two-and-a-half-week timeline.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) found average liraglutide users lost 8.4 kg over 56 weeks, making a 3 kg first-month result plausible but individual variation is high.
- Nausea affects up to 40 percent of liraglutide users and typically resolves during the dose-escalation phase, consistent with the creator's two-and-a-half-week timeline.
- Liraglutide delays gastric emptying and activates hypothalamic GLP-1 receptors, both of which contribute to satiety. Overeating on this drug can cause real pain.
- Weight loss outcomes on liraglutide are significantly better when combined with dietary changes. Not modifying diet is not recommended practice, even if weight loss still occurs.
- Studies show substantial weight regain after stopping liraglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism), meaning this is a long-term treatment decision, not a short course.
- Saxenda and compounded liraglutide are not equivalent products. Compounded versions lack FDA approval and should not be treated as interchangeable with the brand-name drug.
- Saxenda is a prescription medication indicated for BMI 30-plus, or 27-plus with a weight-related comorbidity. Viewing personal results videos is not a substitute for a clinical evaluation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Vero💕 · TikTok creator
117.6K views on this video
Saxenda results, 1 month update #saxenda #results #weightloss #weightlossjouney #saxendajourney
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Vero💕, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.